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Microbiota-dependent metabolite and
cardiovascular disease marker
trimethylamine-N-oxide (TMAO) is
associated with monocyte activation but
not platelet function in untreated HIV
infection
Judith M. Haissman1, Anna K. Haugaard1, Sisse R. Ostrowski2, Rolf K. Berge3,4, Johannes R. Hov5,6,7,8,9,
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Abstract
Background: HIV infection is associated with increased risk of cardiovascular disease beyond that explained by
traditional risk factors. Altered gut microbiota, microbial translocation, and immune activation have been proposed
as potential triggers. The microbiota-dependent metabolite trimethylamine-N-oxide (TMAO) predicts myocardial
infarction (MI) in the general population and has recently been shown to induce platelet hyperreactivity. In the
present study, we investigated if TMAO was associated with platelet function, microbial translocation, and immune
activation in both untreated and combination anti-retroviral therapy (cART) HIV infection.
Methods: TMAO and the pre-cursors betaine, choline, and carnitine were quantified by mass-spectrometry in plasma
samples from a previously established cross-sectional cohort of 50 untreated and 50 cART treated HIV-infected
individuals. Whole-blood impedance aggregometry, C-reactive protein, sCD14, and lipopolysaccharide were assessed as
measures of platelet function, inflammation, monocyte activation, and microbial translocation, respectively.
Results: TMAO was not associated with platelet aggregation response after stimulation with four different agonists, or
with overall hypo- or hyperreactivity in untreated or treated HIV-infected individuals. In contrast, sCD14 a marker of
both monocyte activation and microbial translocation was independently associated with TMAO in untreated HIV-
infection (R = 0.381, P = 0.008). Lower levels of carnitine [32.2 (28.4–36.8) vs. 38.2 (33.6–42.0), P = 0.001] and betaine [33.
1 (27.3–43.4) vs.37.4 (31.5–48.7, P = 0.02], but similar TMAO levels [3.8 (2.3–6.1), vs. 2.9 μM (1.9–4.8) P = 0.15] were found
in cART treated compared to untreated HIV-infected individuals, resulting in higher ratios of TMAO/carnitine [0.12 (0.
07–0.20) vs. 0.08 (0.05–0.11), P = 0.02] and TMAO/betaine [0.11 (0.07–0.17) vs. 0.08 (0.05–0.13), P 0.02].
Conclusions: In contrast to recent studies in HIV-uninfected populations, the present study found no evidence of
TMAO-induced platelet hyperreactivity in HIV infected individuals. Microbial translocation and monocyte activation may
affect TMAO levels in untreated individuals. Furthermore, the elevated ratios of TMAO/betaine and TMAO/carnitine in
cART-treated individuals could possibly suggest a role of cART in TMAO metabolism.
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Background
Since the introduction of combination antiretroviral therapy
(cART), AIDS and HIV-related mortality has declined in
HIV-infected individuals, while cardiovascular disease (CVD)
has emerged as one of the leading causes of morbidity and
mortality [1, 2]. Increasing evidence indicates that HIV infec-
tion is associated with increased risk of CVD beyond that ex-
plained by the higher burden of traditional risk factors
among HIV-infected individuals [3–5]. Numerous non-
traditional mechanisms have been proposed including HIV-
related disruption of the intestinal barrier and changes in the
composition of the intestinal microbiota [6–9]. Several stud-
ies have suggested an important link between intestinal mi-
crobial composition and metabolism and the development of
CVD [10–12]. In the general population, the microbiota
dependent metabolite trimethylamine-N-oxide (TMAO) has
been associated with development of clinical CVD independ-
ently of traditional CVD risk factors [13–21]. Previously,
TMAO was shown to promote atherosclerosis through foam
cell formation and interference with reverse cholesterol trans-
port from the atherosclerotic plaque [13, 17, 22]. In addition,
results from a recent study suggest that TMAO also induces
platelet hyperreactivity [23]. Altered platelet function has
been shown in HIV infection repeatedly [24–26]. We
recently found TMAO to be positively associated a sub-
clinical measure of coronary atherosclerosis in cART treated
HIV-infected individuals [27]. However, we did not find any
difference in TMAO levels in HIV-infected individuals com-
pared to uninfected controls, but an association between
TMAO and cART, especially PI use [27]. Surprisingly,
TMAO was not associated with myocardial infarction (MI)
in cART treated individuals in our previous study [27]. Con-
flicting results have also been found in the small number of
other studies investigating TMAO and CVD in HIV-infected
individuals, and thus the contribution of TMAO to CVD in
HIV infection remains unclear [27–30].
We hypothesized that TMAO would be associated with
platelet function in HIV-infected individuals. Further, as
viral replication, inflammation, monocyte activation,
microbial translocation, and cART have previously been
linked with platelet function in HIV-infected individuals,
we sought to investigate the potential influence of these
factors on TMAO levels in HIV-infected individuals. To
explore this hypothesis, we measured TMAO and the pre-
cursors choline, carnitine, and betaine in stored plasma
from untreated and treated HIV-infected individuals with
previously assessed biomarkers of coagulation activity, in-
flammation, monocyte activation, microbial translocation
and platelet function.
Methods
Cross-sectional cohort
The cohort included 50 HIV-infected, untreated individuals,
from the Department of Infectious Diseases, Copenhagen
University Hospital, and 50 HIV-infected individuals on
cART, selected to match the untreated group for age,
gender, and current CD4+ T-cell count. The cohort has
previously been described in detail [31]. One individual in
the treatment group had detectable viral replication and was
excluded from further analyses. Clinical characteristics of
the study population have previously been described [31].
Briefly, mean age was 40 and 42 years, 90 and 88% were
men, 90 and 86% were Caucasian, 42 and 41% were
current smokers, and mean current CD4+ T-cell count
was 600 and 674 in the HIV-infected untreated and
treated individuals, respectively [31]. Baseline character-
istics are summarized in Table 1.
Platelet function was determined at inclusion by whole-
blood multiple electrode impedance aggregometry, assessing
platelet aggregation in a time-dependent manner as area
under curve after 6 min after stimulation with adenosine di-
phosphate (ADP, concentration 6.5 mmol/l, arachidonic acid
(ASPI, concentration 0.5 mmol/l), collagen (COL, 3.2 mg/
ml), and thrombin receptor agonist peptide (TRAP, concen-
tration 32 mmol/l) on a Multiplate analyzer (Dynabyte
GmBH, Munich, Germany), as previously described [31].
Table 1 Clinical characteristics of the study cohort
Untreated (n = 50) ART-Treated (n = 49) P value
Age, years 41 (33–46) 43 (36–48) 0.249
Sex 90% (45) Male 88% (43) Male 0.722
Etnicity 90% (45) Caucasian 86% (42) Caucasian 0.514
Transmission of HIV 82% (41) MSM 74% (36) MSM 0.618
Current smoker 42% (21) 41% (20) 0.869
HIV-RNA, (copies/mL) 23,026 (5517–90,321) 19 (19–20) < 0.001
Current CD4+ T-cell count, (cells/μL) 560 (415–795) 610 (480–875) 0.363
Duration of HIVa (months) 28 (8–75) 73 (36–151) 0.009
Summary of clinical and demographic characteristics of the study population previously published in [31]. from Continuous data are presented as medians and
(interquartile ranges) and categorical data as percentages and (total numbers). Untreated and treated individuals were compared by Mann-Whitney U test
aDuration since 1st positive HIV-1 test
cART antiretroviral therapy, MSM Men who have sex with men
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Routine biochemistry including standard hemostatic
whole blood tests, and assessment of inflammation, mono-
cyte activation and microbial translocation with C-reactive
protein (CRP), soluble CD14 (sCD14), and lipopolysacchar-
ide (LPS) by quantification with enzyme linked immuno-
sorbent assay (ELISA) and Limulus amebocyte lysate (LAL)
test for LPS, respectively, have previously been performed
[31, 32].
Ethics and informed consent
Plasma samples collected from all participants were
stored at −80 °C until analysis.
The study was conducted in accordance with the
Helsinki-declaration and approved by the Committee on
Biomedical Research Ethics in Denmark (H-2-2009-089)
and the Danish Data Protection Agency. Written in-
formed consent including consent to store plasma and
perform further analysis on blood samples was obtained
from all participants after oral and written information.
Measurement of TMAO
Stable-isotope dilution liquid chromatography with tan-
dem mass spectrometry was used for quantification of
TMAO and pre-cursors choline, carnitine and betaine as
previously described [16, 33]. Valid measurements were
obtained from all samples for betaine, choline and carni-
tine. For TMAO measurements, one sample was a clear
outlier with a result of 52.5 μM, which is much higher
than the 98-percentile of 12.9 μM and therefore excluded
from further analyses.
Statistical analyses
Data are given as median and interquartile range (IQR).
Levels of TMAO and pre-cursors in untreated and treated
groups were compared using Student’s t test after natural
logarithmic (ln) transformation to obtain normal distribu-
tion. Univariate linear regression was performed to investi-
gate possible association with TMAO. Residuals were
checked for normal distribution and ln transformation was
performed when appropriate. Data are given as standard-
ized residuals. Significant univariate associations were in-
vestigated in a multivariate regression model. Independent
variables included sCD14, age and gender as the sample-
size was small. Models including a fifth variable were
created adding one variable at the time. A P-value < 0.05
was considered statistically significant. Analysis was
performed using SPSS 19 (IBM Inc., Armonk, NY).
Results
TMAO was not associated with platelet aggregation
No associations were found between TMAO and standard
coagulation markers i.e. D-dimer, fibrinogen, activated par-
tial tromboplastin time (APTT), coagulation factors II-VII-
X, and platelet count (Table 2). In addition, no associations
were found between TMAO and platelet function evaluated
as platelets aggregation response to ADP, ASPI, COL and
TRAP (Table 2). This was consistent in both untreated and
treated HIV-infected individuals, and platelet aggregation
was evaluated both as a continuous variable and categoric-
ally classified as hyper/hypocoagulable (Table 2). Regression
coefficients and p-values are given in Table 2.
sCD14 was an independent predictor of TMAO in
untreated HIV infection
A positive association was found between TMAO and
sCD14 in untreated HIV-infected individuals, but not in
treated HIV-infected individuals (Table 2). No associations
between TMAO and LPS or CRP were found (Table 2). In
multivariate linear regression models, sCD14 remained an
independent predictor of TMAO after adjustment for age,
gender, and smoking (Table 3). A fifth variable (viral load,
CD4+ T-cell count, LPS, or CRP) was added to the model
one at the time, and sCD14 remained an independent pre-
dictor of TMAO in untreated HIV-infected individuals
with each added variable (Table 3).
TMAO was not associated with HIV-related factors
TMAO was not associated with CD4+ T-cell count, nadir
CD4+ T-cell count, HIV duration or viral load in untreated
HIV-infected individuals, or with CD4+ T-cell count, nadir
CD4+ T-cell count or HIV duration in treated HIV-infected
individuals (Table 2). Neither was TMAO associated with
cART regimens (Table 2). No associations between TMAO
and gender or smoking status were found in either
untreated or treated HIV-infected individuals (Table 2). A
weak positive association was found between TMAO and
age in treated HIV-infected individuals. The association
with age was not found in untreated individuals.
TMAO and precursors in untreated vs. cART treated HIV-
infected individuals
TMAO levels were not significantly different in untreated
vs. treated HIV-infected individuals [2.9 μM (1.9–4.8) vs.
3.8 (2.3–6.1), P = 0.15] (Fig.1d). However, elevated carni-
tine [38.2 (33.6–42.0) vs. 32.2 (28.4–36.8), P = 0.001] and
betaine [37.4 (31.5–48.7 vs. 33.1 (27.3–43.4), P = 0.02],
but not choline [7.9 (6.8–10.3) vs. 8.4 (7.2–10.1), P = 0.40]
were found in untreated compared to treated HIV-
infected individuals (Fig. 1a, 1b, 1c). This resulted in
elevated ratios of TMAO/carnitine [0.12 (0.07–0.20) vs.
0.08 (0.05–0.11), P = 0.02] (Fig. 1e) and TMAO/betaine
[0.11 (0.07–0.17) vs. 0.08 (0.05–0.13), P 0.02] (Fig. 1f), but
not TMAO/choline [0.45 (0.31–0.69) vs. 0.35 (0.26–0.55),
P = 0.25] in treated compared to untreated HIV-infected
individuals. Elevated ratios remained after adjusting for
sCD14 and viral load using multivariate analysis of
variance (ANOVA) (data not shown).
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Discussion
In this study including 50 untreated and 50 cART treated
HIV-infected individuals no associations were found be-
tween TMAO and platelet function. In contrast, TMAO
was independently associated with sCD14 in untreated but
not in treated HIV-infected individuals. Furthermore, sig-
nificantly elevated ratios of TMAO over pre-cursors were
found in treated compared to untreated HIV-infection.
In the general population, there is increasing appreciation
that changes in the composition and function of the gut
microbiota can promote long-term susceptibility to CVD
[34]. The gut microbe-derived metabolite TMAO has been
recognized as an important contributor in this process, and
recent evidence points towards TMAO induced platelet hy-
perreactivity as a potential pathogenic mechanism [23]. We
were not able to confirm this finding in an HIV-infected co-
hort. The explanation of the lacking association between
TMAO and platelet function could be, that other factors
have a stronger effect on platelet function in HIV-infected
individuals than TMAO, thus diluting the direct effect of
Table 2 Univariate linear regression with TMAO as the dependent variable
Untreated (n = 49) ART Treated (n = 49)
Standardized β coefficients P Standardized β coefficients P
Clinical characteristics:
Age (years) 0.180 0.21 0.290 0.04
Gender, male 0.137 0.34 0.110 0.94
Current smoker, 0.129 0.39 −0.182 0.24
Current CD4+ T cell count (cells/μl) 0.035 0.81 0.084 0.57
Nadir CD4+ T cell count (cells/μl) −0.081 0.58 0.087 0.55
HIV-RNA (103 copies/ml) −0.010 0.94 NA NA
HIV duration 0.078 0.59 0.070 0.64
Class of ART
NRTI containing (n = 44) NA NA 0.043 0.78
NNRTI containing (n = 22) NA NA 0.135 0.38
PI containing (n = 23) NA NA 0.145 0.34
II containing (n = 4) NA NA −0.024 0.87
Abacavir containing (n = 16) NA NA −0.126 0.41
Standard coagulation
D-dimer 0.051 0.74 0.209 0.16
Fibrinogen 0.091 0.55 0.183 0.24
APTT 0.117 0.43 0.171 0.27
Coagulation factors 2–7-10 0.043 0.77 0.032 0.83
Platelet aggregation (Multiplate):
ADP test (Units) −0.074 0.62 −0.177 0.23
ASPI test (Units) −0.156 0.29 −0.243 0.10
COL test (Units) −0.080 0.59 −0.211 0.15
TRAP test (Units) −0.119 0.42 −0.220 0.13
Hypocoagulable in ≥2/4 tests 0.007 0.97 0.147 0.32
Hypercoagulable in ≥2/4 tests −0.172 0.24 NA NA
Markers of Microbial translocation and inflammation:
sCD14 (ρg/ml) 0.454 0.001 −0.157 0.28
LPS (ρg/ml) −0.019 0.90 0.047 0.75
hsCRP −0.016 0.92 0.028 0.37
Univariate linear regression with trimethylamine-N-oxide (TMAO) as the dependent variable. Standardized regression coefficients and P values are given. Standard
coagulation, and platelet impedance aggregometry are given as continuous variables and classified as hypo- and hypercoagulable according to normal range
APTT activated partial thromboplastin time, ART anti-retroviral therapy, ASPI arachidonic acid, COL collagen, FEU fibrinogen equivalent units, II integrase Inhibitor, n
number, NA not applicable, NRTI nucleotide/nucleoside reverse transcription inhibitor, NNRTI non-nucleoside reverse transcription inhibitor, PI protease Inhibitor,
sCD14 soluble CD14, TRAP thrombin-receptor activating peptide
Significant associations are marked in bold
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TMAO on platelet function. Indeed, previous studies in
HIV-infected populations indicate that both immune acti-
vation, viral replication, specific cART drug classes lead to
platelet activation and dysfunction [24, 31, 35, 36].
Further, some of these factors might potentially interfere
with TMAO levels. Indeed, a strong association was found
between sCD14 and TMAO in untreated HIV-infected in-
dividuals. This association remained significant after ad-
justment for demographic and HIV-related factors. sCD14
is secreted from activated monocytes upon binding of the
microbial product LPS to the toll like receptor (TLR)-4
[37, 38]. Thus, sCD14 can be used as a marker of both
monocyte activation and microbial translocation. Recent
evidence suggests that microbial translocation is accom-
panied by alterations in the composition of the gastro-
intestinal microbiota [6–8, 39]. Hence, the association
between sCD14 and TMAO in our study could imply that
a gut microbiota composition associated with microbial
translocation might be of a phenotype that produce higher
Table 3 Multiple Linear Regression Models with TMAO as
Dependent Variable
Characteristics Standardized β coefficient P
Age 0.233 0.10
Gender 0.079 0.58
Smoking 0.123 0.39
sCD14 0.381 0.008
Model with additional adjustment for each of the following variables
CD4+ T-cell count 0.379 0.010
Viral load 0.452 0.003
hsCRP 0.304 0.045
LPS 0.384 0.009
Multivariate linear regression analyses with TMAO as dependent variable.
Standardized β coefficients for TMAO are given after adjustment for a fifth
variable. sCD14, soluble CD14, TMAO, Trimethylamine-N-oxide
Fig. 1 Trimethylamine-N-oxide (TMAO), pre-cursors and TMAO/pre-cursor ratios in untreated compared to cART treated individuals. Comparison
of untreated (n = 49) and treated (n = 49) HIV-infected individuals of levels of Carnitine (a), Betaine (b), Choline (c), and TMAO (d), and ratios of
TMAO/Carnitine (e), TMAO/Betaine (f) For each group median and interquartile ranges are shown. Data was ln-transformed and student t-test
was used to compare groups, and P-values are given for each comparison
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levels of TMAO. To our knowledge, no previous studies
have found a link between microbial translocation, mono-
cyte activation, and TMAO. However, associations be-
tween TMAO and systemic inflammatory marker CRP or
microbial translocation marker LPS were not found. Both
markers are known to be volatile, and previous studies
have reported lacking or weak associations between LPS
and CRP and other markers of microbial translocation
and systemic inflammation [40–43]. Further, interpret-
ation of the association between sCD14 and TMAO as
proof of the impact of microbial translocation on plasma
TMAO cannot be inferred. CD14 is also a co-receptor for
other TLRs and microbial products other than LPS. Thus,
elevated sCD14 is not strictly induced by microbial trans-
location and therefore also a marker of more general
monocyte activation.
Elevated betaine and carnitine were found in untreated
compared to treated HIV-infected individuals. Both the
endogenously produced metabolite betaine and the diet-
ary metabolite carnitine can be metabolized to TMAO
by gut microbiota [12, 18]. Both pre-cursors have also
been associated with CVD [44], although a recent study
suggests that this association is mediated through the
concomitant increase in TMAO [18]. As we do not have
any information on dietary intake, an effect of diet on
carnitine levels, particularly increased intake of red meat,
cannot be excluded. However, the increased ratios of
TMAO over both endogenous and diet dependent pre-
cursors in cART treated individuals suggest the involve-
ment of other mechanisms. We and others have previ-
ously found elevated TMAO associated with cART
treatment, especially PI-treatment [27, 45]. The elevated
ratios of TMAO over pre-cursors in cART treated indi-
viduals may suggest that cART interferes with TMAO
metabolism, possibly by inducing hepatic flavin-
containing monooxygenases resulting in increased con-
version from TMA to TMAO. Commencement of cART
therapy leads to several other changes including sup-
pression of viral replication and concomitant attenuation
of immune activation. Thus, changes in these factors
could also be the cause of the observed changes in
TMAO production and metabolism observed in the
study. However, even after adjusting for viral replication
and monocyte activation increased ratios of TMAO over
precursors betaine and carnitine remained in cART
treated individuals. These results offer a possible explan-
ation for the lacking power of TMAO in predicting MI
in cART treated HIV-infected individuals [27], and for
the association between TMAO and sCD14 found in
only untreated and not cART treated individuals in this
study. However, as the study populations of untreated
and cART treated HIV-infected infected individuals dif-
fer on several important known and unknown factors
e.g. HIV duration, illicit drug use, socioeconomic status,
dietary habits. These additional factors might also ac-
count for the elevated ratios and pre-cursors in cART
treated individuals.
The study was limited by the cross-sectional design, ren-
dering conclusions on causality unanswered. In contrast to
previous results [27, 45], no association of TMAO and PI
use was found. However, this might be due to the small
number of participants on different ART regimens (n = 23,
PI), increasing the risk of type two statistical errors. Lacking
power due to limited number of participants and high vari-
ance in TMAO concentrations, might also explain why the
elevation of TMAO in treated compared to untreated indi-
viduals did not reach statistical significance. Methodology
for assessing platelet function differed from the study that
found TMAO induced hyperreactivity in platelets from
HIV-uninfected individuals [23]. Platelet aggregation was
assessed by measuring changes of impedance in electrodes
after stimulation with four different stimulants including
ADP (Multiple electrode aggregation, Multiplate) [31]. In
the study by Zhu et al. aggregation was assessed by changes
in light transmission after stimulation with ADP and
thrombin (light transmission aggregation, LTA) [23]. Even
though one of the same stimulants was used in both stud-
ies, the slight differences in methodology might account for
the different findings, and concentrations of stimulants can-
not be directly compared [46]. Further, impedance aggrego-
metry utilizes whole-blood samples without prior
manipulation, rendering the method closer to the biological
environment compared to the platelet rich plasma utilized
in LTA, where platelets prior to use have been centrifuged
possibly inducing activation or damage. Additional methods
for evaluating platelet function and an HIV-uninfected con-
trol group could have helped distinguish between specific
HIV-related effects and missing associations due to meth-
odical issues. Furthermore, additional markers of immune
activation independent of microbial translocation, other
markers specifically assessing microbial translocation in
addition to LPS, and an assessment of the microbial com-
position of the study participants would have facilitated the
exploration of the specific effects of immune activation in
opposition to microbial translocation and composition on
TMAO levels. Finally, the analyses were conducted on a
previously established study population.
Conclusions
In conclusion, no evidence of TMAO being associated with
platelet hyperreactivity was found in an HIV-infected study
population. This result is in contradiction to findings from a
study in HIV-uninfected individuals. Interestingly, TMAO
was independently associated with sCD14 in untreated HIV-
infected individuals, suggesting that microbial translocation
and monocyte activation may affect TMAO levels. Further-
more, the elevated ratios of TMAO/betaine and TMAO/
carnitine in cART-treated individuals suggest an altered
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TMAO metabolism in cART treated-individuals. Our
findings call for further studies in HIV-infected populations
specifically designed to investigate the potential role of gut
microbiota composition and related metabolites, beyond
TMAO, on CVD risk. Furthermore, the elevated ratios of
TMAO/betaine and TMAO/carnitine in cART-treated indi-
viduals suggest an altered TMAO metabolism in cART
treated-individuals. This is also an important avenue of fu-
ture research to explore, as the altered metabolism sug-
gested from these and previous findings, might have an
impact on CVD risk in cART treated HIV-infected
individuals.
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